Cited by 117Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 53 of the 55 references it cites were found in a registry or an index.

Apolipoproteins as markers and managers of coronary risk

Chan, D.C.·2006·QJM

DOI 10.1093/qjmed/hcl027

Open this paper in CoChat — free account

Abstract

Coronary artery disease (CAD) is a major cause of morbidity and mortality in Western communities. Reliable indices of coronary risk assessment and targets for drug treatment are important to the management of patients. Although plasma LDL cholesterol is well established as a predictor of CAD, it may not be the best circulatory marker. Results from recent epidemiological studies and statin trials suggest that apolipoprotein B-100 (apoB), with or without apoA-I, is superior to LDL cholesterol in predicting coronary events. Measurements of apolipoproteins are internationally standardized, automated, cost-effective and more convenient and precise than those for LDL cholesterol. ApoB may also be preferable to the measurement of non-HDL cholesterol. Measurement of apolipoproteins (apoB and possibly apoA-I) should be routinely added to the routine lipid profile (cholesterol, triglycerides and high-density lipoprotein cholesterol) to assess the atherogenic potential of lipid disorders. This is particularly relevant to dyslipidaemias characterized by an elevation in plasma triglycerides. Apolipoproteins, especially apoB, could also replace the standard "lipid profile" as a target for therapy in at-risk patients.

Integrity signals

Registry

Crossref · 10.1093/qjmed/hcl027

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
The metabolic syndrome
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Bairey Merz, C. N., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.001 · Cited by 1,550
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227

Show all 55 references

Sorted by citations

Indian Journal of Public Health Research & Development
Surwade, V. M., Ambedkar, B. S., Rohinee, & Delhi (2019) · Cited by 404
Ellagitannins, ellagic acid and vascular health
Larrosa, M., García‐Conesa, M., Espı́n, J. C., & Tomás-Barberán, F. A. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.09.005 · Cited by 390
Mechanisms of Action of trans Fatty Acids
Oteng, A., & Kersten, S. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz125 · Cited by 331
Screening and Treatment for Lipid Disorders in Children and Adolescents: Systematic Evidence Review for the US Preventive Services Task Force
Haney, E. M., Huffman, L. H., Bougatsos, C., Freeman, M., Steiner, R. D., & Nelson, H. D. (2007) · PEDIATRICS · doi:10.1542/peds.2006-1801 · Cited by 202
Apolipoproteins and cancer
Ren, L., Yi, J., Li, W., Zheng, X., Liu, J., Wang, J., & Du, G. (2019) · Cancer Medicine · doi:10.1002/cam4.2587 · Cited by 145
There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness
Makover, M. E., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100371 · Cited by 139
Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study: The Suita study
Okamura, T., Kokubo, Y., Watanabe, M., Higashiyama, A., Miyamoto, Y., Yoshimasa, Y., & Okayama, A. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.020 · Cited by 123
The role of damage- and pathogen-associated molecular patterns in inflammation-mediated vulnerability of atherosclerotic plaques
Rai, V., & Agrawal, D. K. (2017) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2016-0664 · Cited by 103
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia · doi:10.1007/s00125-010-1806-9 · Cited by 94
Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke
Walldius, G., & Jungner, I. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3281bd8849 · Cited by 76
MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?
Burnett, J. R., & Watts, G. F. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.181 · Cited by 58
Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial
Lerman, R. H., Minich, D. M., Darland, G. K., Lamb, J. J., Schiltz, B., Babish, J. G., Bland, J. S., & Tripp, M. L. (2008) · Nutrition & Metabolism · doi:10.1186/1743-7075-5-29 · Cited by 56
Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment
Galimberti, F., Casula, M., & Olmastroni, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106873 · Cited by 63
Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus
Kadoglou, N. P. E., Iliadis, F. S., Sailer, N., Athanasiadou, Z. S., Vitta, I., Kapelouzou, A., Karayannacos, P. E., Liapis, C. D., Alevizos, M., Angelopoulou, N., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.09.002 · Cited by 55
Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease
Hyysalo, J., Stojkovic, I., Kotronen, A., Hakkarainen, A., Sevastianova, K., Makkonen, J., Lundbom, N. M. I., Rissanen, A., Krauss, R. M., Melander, O., et al. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07045.x · Cited by 55
The Transcription Profile Unveils the Cardioprotective Effect of Aspalathin against Lipid Toxicity in an In Vitro H9c2 Model
Johnson, R., Dludla, P. V., Muller, C. J. F., Huisamen, B., Essop, M. F., & Louw, J. (2017) · Molecules · doi:10.3390/molecules22020219 · Cited by 54
Genetic Dominance Influences Blood Biomarker Levels in a Sample of 12,000 Swedish Elderly Twins
Rahman, I., Bennet, A. M., Pedersen, N. L., Fairé, U. D., Svensson, P., & Magnusson, P. K. E. (2009) · Twin Research and Human Genetics · doi:10.1375/twin.12.3.286 · Cited by 48
Acute effects of vinegar intake on some biochemical risk factors of atherosclerosis in hypercholesterolemic rabbits
Setorki, M., Asgary, S., Eidi, A., Rohani, A. H., & Khazaei, M. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-10 · Cited by 50
Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I – new risk factors and targets for therapy
Walldius, G., & Jungner, I. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.02.010 · Cited by 48
Dyslipidemia and Its Role in the Pathogenesis of Atherosclerotic Cardiovascular Disease: Implications for Evaluation and Targets for Treatment of Dyslipidemia Based on Recent Guidelines
Wengrofsky, P., Lee, J., & Makaryus, A. N. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85772 · Cited by 54
Intracellular role of exchangeable apolipoproteins in energy homeostasis, obesity and non‐alcoholic fatty liver disease
Wu, C., Zhao, S., & Yu, B. (2014) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12116 · Cited by 45
Future Challenges for Microsomal Transport Protein Inhibitors
Wierzbicki, A. S., Hardman, T. C., & Prince, W. (2009) · Current Vascular Pharmacology · doi:10.2174/157016109788340703 · Cited by 45
Crossroads between peripheral atherosclerosis, western-type diet and skeletal muscle pathophysiology: emphasis on apolipoprotein E deficiency and peripheral arterial disease
Sfyri, P., & Matsakas, A. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0346-8 · Cited by 44
O-Glycoside Biomarker of Apolipoprotein C3: Responsiveness to Obesity, Bariatric Surgery, and Therapy with Metformin, to Chronic or Severe Liver Disease and to Mortality in Severe Sepsis and Graft vs Host Disease
Harvey, S. B., Zhang, Y., Wilson‐Grady, J., Monkkonen, T., Nelsestuen, G. L., Kasthuri, R. S., Verneris, M. R., Lund, T. C., Ely, E. W., Bernard, G. R., et al. (2008) · Journal of Proteome Research · doi:10.1021/pr800751x · Cited by 43
The Visceral Adiposity Index: Relationship with cardiometabolic risk factors in obese and overweight postmenopausal women – A MONET group study
Elisha, B., Messier, V., Karelis, A. D., Coderre, L., Bernard, S., Prud’homme, D., & RABASA-LHORET, R. P. R. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2012-0307 · Cited by 43
Special Supplemental Nutrition Program For Women, Infants, and Children
Guide, C. W. F. (2011) · Cited by 42
The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.001 · Cited by 42
Self-citation
Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes
Tuomikoski, P., Mikkola, T. S., Hämäläinen, E. K., Tikkanen, M. J., Turpeinen, U., & Ylikorkala, O. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181acefd5 · Cited by 33
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.04.005 · Cited by 33
Self-citation
Estimating the Effect of Aerobic Exercise Training on Novel Lipid Biomarkers: A Systematic Review and Multivariate Meta-Analysis of Randomized Controlled Trials
Wood, G., Taylor, E., Ng, V., Murrell, A., Patil, A., van der Touw, T., Wolden, M., Andronicos, N., & Smart, N. A. (2023) · Sports Medicine · doi:10.1007/s40279-023-01817-0 · Cited by 31
Índice apo B/apo A-I e predição de risco cardiovascular
Lima, L. M., Ferriani, M. D. G. C., & Sousa, M. O. (2007) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2007000600014 · Cited by 31
Efficacy of new beverage made of dates vinegar and garlic juice in improving serum lipid profile parameters and inflammatory biomarkers of mildly hyperlipidemic adults: A double-blinded, randomized, placebo-controlled study
Ali, Z., Ma, H., Ayim, I., & Wali, A. (2018) · Journal of Food Biochemistry · doi:10.1111/jfbc.12545 · Cited by 28
Menopausal hot flushes and vascular health
Tuomikoski, P., Ylikorkala, O., & Mikkola, T. S. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.546364 · Cited by 28
Apolipoprotein B is related to arterial pulse wave velocity in young adults: The Cardiovascular Risk in Young Finns Study
Koivistoinen, T., Hutri‐Kähönen, N., Juonala, M., Kööbi, T., Aatola, H., Lehtimäki, T. J., Viikari, J. S. A., Raitakari, O. T., & Kähönen, M. A. P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.037 · Cited by 27
ApoE Genotype, Lipid Profile, Exercise, and the Associations With Cardiovascular Morbidity and 18-Year Mortality
Dankner, R. S., Avraham, S. B., Harats, D., & Chetrit, A. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz232 · Cited by 27
Lipid Profile, Apolipoproteins A and B in Children With Epilepsy
Tomoum, H. Y., Awadallah, M., Fouad, D. A., & Ali, A. H. (2008) · Journal of Child Neurology · doi:10.1177/0883073808318538 · Cited by 25
The strengths and limitations of the ApoB/ApoA-I ratio to predict the risk of vascular disease: a hegelian analysis
Sniderman, A. D., & Kiss, R. S. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0031-6 · Cited by 22
Regulation of Apolipoprotein B by Natural Products and Nutraceuticals: A Comprehensive Review
Bagherniya, M., Johnston, T. P., & Sahebkar, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200427092114 · Cited by 22
Role of Short Chain Fatty Acids and Apolipoproteins in the Regulation of Eosinophilia-Associated Diseases
Sturm, E. M., Knuplez, E., & Marsche, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094377 · Cited by 21
Serum Metabolomics Study of Gliclazide-Modified-Release-Treated Type 2 Diabetes Mellitus Patients Using a Gas Chromatography–Mass Spectrometry Method
Zhou, Y., Hu, C., Zhao, X., Luo, P., Lu, J., Li, Q., Chen, M., Yan, D., Lu, X., Kong, H., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00866 · Cited by 21
Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case–Control Study
Wu, T., Zheng, Y., Yang, Y., Li, X., Ma, Y.-T., & Xie, X. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0067 · Cited by 21
Molecular signatures of atherosclerotic plaques: An up-dated panel of protein related markers
Eslava-Alcón, S., Extremera-García, M. J., González-Rovira, A., Rosal‐Vela, A., Rojas-Torres, M., Beltrán-Camacho, L., Sánchez-Gomar, I., Jiménez-Palomares, M., Alonso-Piñero, J. A., Conejero, R. C., et al. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103757 · Cited by 22
Low serum adiponectin levels are associated with reduced insulin sensitivity and lipid disturbances in short children born small for gestational age
Huang, Y., Li, Y., Chen, Q., Chen, H.-S., Ma, H., Su, Z., & Du, M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12663 · Cited by 20
How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes
Sypniewska, G., Bergmann, K., Krintus, M., Koziński, M., & Kubica, J. (2011) · Journal of Medical Biochemistry · doi:10.2478/v10011-011-0022-6 · Cited by 19
Serum proteome profiling in canine chronic valve disease using a TMT-based quantitative proteomics approach
Kuleš, J., Bilić, P., Horvatić, A., Kovačević, A., Guillemin, N., Ljubić, B. B., Galán, A., Jović, I., Torti, M., Rubić, I., et al. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103825 · Cited by 18
Randomized placebo-controlled trial of Mustadi Ghanavati in hyperlipidemia
Nadkarni, M., Vyas, S., Baghel, M., & Ravishankar, B. (2010) · AYU (An International Quarterly Journal of Research in Ayurveda) · doi:10.4103/0974-8520.77150 · Cited by 17
Relevance of Lipoprotein Composition in Endothelial Dysfunction and the Development of Hypertension
Ramírez-Melo, L. M., Estrada-Luna, D., Rubio-Ruiz, M. E., Ovando, A. C., Fernández‐Martínez, E., Jiménez‐Osorio, A. S., Pérez-Méndez, O. A., & Carreón‐Torres, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031125 · Cited by 13
Polimorfismos de los genes APOA1 y APOB y concentraciones de sus apolipoproteínas como biomarcadores de riesgo en el síndrome coronario agudo: relación con la efectividad del tratamiento hipolipemiante
Casillas-Muñoz, F. A. G., Valle, Y., Muñóz-Valle, J. F., Martínez-Fernández, D. E., Reynoso-Villalpando, G. L., Flores-Salinas, H. E., Llamas-Covarrubias, M. A., & Padilla‐Gutiérrez, J. R. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.07.026 · Cited by 14
Acute modification in plasma lipid levels in ultramarathon runners
Emed, L. G. M., Passaglia, D. G., Guerios, S. T., David-João, P. G., Moser, A. I., Abdalla, D. S. P., Guarita-Souza, L. C., Mikilita, E. S., Baena, C. P., da Costa, A. B. B. A., et al. (2015) · Journal of Sports Sciences · doi:10.1080/02640414.2015.1130237 · Cited by 14
APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness
Casillas-Muñoz, F. A. G., Valle, Y., Muñóz-Valle, J. F., Martínez-Fernández, D. E., Reynoso-Villalpando, G. L., Flores-Salinas, H. E., Llamas-Covarrubias, M. A., & Padilla‐Gutiérrez, J. R. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.05.001 · Cited by 14
Apolipoprotein B Levels Predict Future Development of Hypertension Independent of Visceral Adiposity and Insulin Sensitivity
Han, S. J., Fujimoto, W. Y., Kahn, S. E., Leonetti, D. L., & Boyko, E. J. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.351 · Cited by 13
Impact of an integrated obesity management system on patient’s care - research protocol
Baillargeon, J., Tribble, D. S., Xhignesse, M., Grant, A., Brown, C., & Langlois, M. (2014) · BMC Obesity · doi:10.1186/s40608-014-0019-z · Cited by 15
The Use of Biomarkers for the Early Detection of Vulnerable Atherosclerotic Plaques and Vulnerable Patients. A Review
Benedek, T., Maurovich‐Horvat, P., Ferdinandy, P., & Merkely, B. P. (2016) · Journal of Cardiovascular Emergencies · doi:10.1515/jce-2016-0017 · Cited by 12
Dietary oil modifies the plasma proteome during aging in the rat
González, M. S., López‐Miranda, J., Pérez‐Jiménez, F., Navas, P., & Villalba, J. M. (2011) · AGE · doi:10.1007/s11357-011-9239-z · Cited by 12
High prevalence of subclinical atherosclerosis in Brazilian postmenopausal women with low and intermediate risk by Framingham score
Petisco, A. C. G. P., Assef, J. E., de Jesus, C. A., Saleh, M. H., Barbosa, J. E. M., Bihan, D. C. D. S. L., Pinto, I. F. M., Pedra, S. R. F. F., Barretto, R. B. D. M., & Sousa, A. (2016) · International journal of cardiac imaging · doi:10.1007/s10554-016-1002-1 · Cited by 11
Lipids and atherosclerosis
Djerić, M., Stokić, E., Vučković, B., Kojić-Damjanov, S., & Čabarkapa, V. (2006) · Jugoslovenska medicinska biohemija · doi:10.2298/jmb0604325d · Cited by 11
Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy
Tuomikoski, P., Mikkola, T. S., Tikkanen, M. J., & Ylikorkala, O. (2010) · Climacteric · doi:10.3109/13697131003624656 · Cited by 11
The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results
Santos‐Gallego, C. G., Torres, F., & Badimón, J. J. (2011) · Clinical Lipidology · doi:10.2217/clp.10.90 · Cited by 10
Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non–HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes
Weinstock, R. S., Goldberg, R. B., Guyton, J. R., Mazzone, T., Polis, A. B., Tomassini, J. E., Lin, J., Shah, A. K., & Tershakovec, A. M. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.01.001 · Cited by 9
Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice
Patel, O., Muller, C. J. F., Joubert, E., Rosenkranz, B., Louw, J., & Awortwe, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251069 · Cited by 9
Reduces cholesterol induced atherosclerotic lesions in aorta artery in hypercholesterolemic rabbits
Setorki, M., Asgary, S., Javanmard, S. H., & Nazari, B. (2011) · Journal of Medicinal Plants Research · doi:10.5897/jmpr.9001077 · Cited by 9
Biochemical Markers of Atherosclerosis
Đerić, M., Kojić-Damjanov, S., Čabarkapa, V., & Eremić, N. (2008) · Journal of Medical Biochemistry · doi:10.2478/v10011-008-0008-1 · Cited by 9
Niveles plasmáticos de apolipoproteínas en una población saludable de la Argentina: implicaciones en prevención cardiovascular
Siniawski, D. A., Masson, W. M., Bluro, I. M., Sorroche, P. B., Scordo, W., Krauss, J. G., & Cagide, A. M. (2025) · Revista Argentina de Cardiología · doi:10.7775/rac.v77i2.2158 · Cited by 6
The association between eosinophil count, serum lipids and metabolic syndrome in Taiwanese
Lin, W., & Chen, J. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.07.015 · Cited by 7
Dyslipidemia in Obesity
Chan, D. C., Pang, J., & Watts, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_30 · Cited by 10
Self-citation
Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go
Sniderman, A. D. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32809f951a · Cited by 7
Association Between Apo Lipoprotein B Levels at Admission of Patientsand Short-term Morbidity and Mortality After Myocardial Infarction
Sokhanvar, S., Khoshi, A., Hajiaghaei, S., Mousavinasab, S. N., & Golmohammadi, Z. (2012) · Europe PMC (PubMed Central) · doi:10.5681/jcvtr.2012.015 · Cited by 6
Serum 25-hydroxyvitamin D3 is associated with homocysteine more than with apolipoprotein B
Kim, N.-K., Jung, M.-A., Choi, B. H., & Joo, N. (2022) · Nutrition Research and Practice · doi:10.4162/nrp.2022.16.6.745 · Cited by 6
Role of FGF21 and Leptin for the Diagnosis of Metabolic Health in Children with and without Obesity
Domouzoglou, E. M., Vlahos, A. P., Papafaklis, M. I., Cholevas, V., Chaliasos, N., Siomou, E. C., Michalis, L. K., Tsatsoulis, A. A., & Naka, K. Κ. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13121680 · Cited by 5
Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis.
Kirmizis, D. A., Koutoupa, E., Tsiandoulas, A., Valtopoulou, A., Niavis, G., Markou, P., & Barboutis, K. (2007) · PubMed Central · Cited by 5
Estimating LDL ApoB: Infomania or Clinical Advance?
Burnett, J. R., & Watts, G. F. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.104505 · Cited by 5
Evaluation of Lipid Metabolism among Sudanese Patients with Type 2 Diabetes Mellitus
Elfaki, E. M., Mohamed, E., Raheem, A., Ahmed, S. E., & Arabia, S. (2014) · Cited by 4
High-sensitivity C-reactive protein, apolipoproteins, and residual diuresis in chronic kidney disease patients undergoing hemodialysis
Borges, D. L., Lemes, H. P., Ferreira, V. D. C., & Filho, S. R. F. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1230-7 · Cited by 4
Dyslipidemia in Obesity
Chan, D. C., Pang, J., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_30-1 · Cited by 5
Self-citation
Bromuconazole exposure induces cardiac dysfunction by upregulating the expression LEF1
Huang, Y., Gu, W., Qin, Z., & Jin, Y. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.173113 · Cited by 4
RETRACTED: Extracellular vesicles loaded with ApoB-100 protein affect the occurrence of coronary heart disease in patients after injury of spinal cord
Wu, C., Chen, J., Zhang, J., Hong, H., Jiang, J., Ji, C., Li, C., Xia, M., Xu, G., & Cui, Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134330 · Cited by 4
Retracted
Association of Paraoxonase1 Gene Q192R Polymorphism and Apolipoprotein B in Asian Indian Women with Coronary Artery Disease Risk
Deshpande, C. S., Singhal, R. S., & Mukherjee, M. S. (2012) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0193 · Cited by 4
Correlation between Apolipoprotein B-to-Apolipoprotein A1 Ratio and Total-to-HDL-Cholesterol Ratio in a Healthy Population: Should Castelli Index be Updated?
Siniawski, D. A., Masson, W. M., Sorroche, P. B., Casañas, L., & Krauss, J. G. (2011) · Dialnet (Universidad de la Rioja) · doi:10.7775/rac.79.1.554 · Cited by 3
The correlation between serum Apo lipoprotein A1 and Apo lipoprotein B with coronary artery disease and its severity
Mashaykhi, N. R., Sadrneya, S., Chehrei, A., Javaheri, J., & Ahmadlou, M. (2013) · مجله دانشگاه علوم پزشکی اراک · Cited by 3
Association Between Apolipoprotein B and Coronary Artery Disease Among Hypertensive Patients: A Systematic Review of the Prospective and Retrospective Studies
Nathir, I., Aziz, F. A., & Hashim, R. D. (2023) · Cureus · doi:10.7759/cureus.49854 · Cited by 2
Apolipoprotein L3 inhibits breast cancer proliferation and modulates cell cycle via the P53 pathway
Yu, H., Li, S., Li, X., Liu, Y., Wang, Z., Cui, M., Jin, F., & Yu, X. (2024) · Journal of Cancer · doi:10.7150/jca.96903 · Cited by 2
Microwave radiation exposures affect the ldl, hdl, tcl and trg status in rats
Aweda, M. A., Gbenebitse, S., & Meindinyo, R. O. K. (2010) · International Journal of the Physical Sciences · doi:10.5897/ijps.9000370 · Cited by 2
The Safety and Efficacy of Statin Therapy in the Pediatric Population
Robbins, D. A. (2011) · The Journal of Cardiovascular Nursing · doi:10.1097/jcn.0b013e3181e19a82 · Cited by 2
Serum Lipid Profile Constituents as Markers of Cardiovascular Morbidity in Patients on Chronic Hemodialysis
Kirmizis, D. A., Koutoupa, E., Tsiandoulas, A., Valtopoulou, A., Niavis, G., Markou, P., & Barboutis, K. (2006) · Biomarker Insights · doi:10.1177/117727190600100010 · Cited by 6
Postmenopausal hot flushes, vascular health and hormone therapy
Tuomikoski, P. (2010) · Työväentutkimus Vuosikirja · Cited by 2
Biomarkers of Cardiovascular Disorders
Jain, K. K. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-685-6_8 · Cited by 1
Significance of Determining Levels of Apolipoproteins A-I and B in the Diagnostics and Assessment of Lipid-Related Atherogenic Risk in Hyperalpha-Lipoproteinemia, Hypocholesterolemia and Hypo-Hdl-Cholesterolemia
Kojić-Damjanov, S., Đerić, M., Čabarkapa, V., & Vučurević-Ristić, L. (2007) · Journal of Medical Biochemistry · doi:10.2478/v10011-007-0024-6 · Cited by 1
Evaluation of Endothelial Function in Pre-Menopausal Women With Coronary Arterial Disease
Farias, W. K. D. S., Rocha, T. P. O., de Melo, J. B., Fonseca, É. J. N. D. C., Fernandes, D. R., Pontes, L. P. P., Andrade, M. V. G., & Neto, J. A. D. F. (2017) · International Journal of Cardiovascular Sciences · doi:10.5935/2359-4802.20170043 · Cited by 1
Comparison of Apolipoprotein Concentrations and Values of APOB:APOAI with Traditional Lipid Measures in Women Diagnosed with Acute Cornonary Syndromes - A Preliminary Report.
Krintus, M., Bergmann, K., Sypniewska, G., & Sawicki, M. (2011) · PubMed Central · Cited by 1
Association of Apolipoprotein B and Triglyceride Levels with Coronary Artery Disease
Habib, H., Haroon, Z. H., Aamir, M. B., Bibi, A., Javed, H., & Jaffar, S. R. (2022) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v72i5.6114 · Cited by 1
Studies on the atherogenicity of apoB-containing lipoproteins in type 2 diabetes
Pettersson, C. (2009) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Inflamação, apolipoproteínas e diurese residual em pacientes com doença renal crônica em hemodiálise: um estudo observacional
Borges, D. L. (2014) · doi:10.14393/ufu.di.2018.3 · Cited by 1
Lipoprotein (a) in Sudanese diabetic patients correlated with glycosylated heamoglobin
Ahmed, E. M. (2014)
Análise da relação de qualidade da dieta com nível de atividade física e destes com perfil lipídico e estado inflamatório em indivíduos de risco cardiometabólico
Pires, M. M. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.6.2011.tde-14092011-094751
Prevalência da aterosclerose subclínica em mulheres na pós-menopausa com risco cardiovascular baixo e intermediário estimado pelo escore de Framingham
Petisco, A. C. G. P. (2014) · doi:10.11606/t.98.2014.tde-15072014-090843
Programa de intervenção interdisciplinar em hábitos de vida em indivíduos de risco cardiometabólico: análise de fatores dietéticos associados à melhora do metabolismo glicídico
de Barros, C. R. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2012.tde-07112012-103357
Assessment of Lipoprotein (a) In Blood Samples of Sudanese Diabetic Patients Correlated With Glycosylated Heamoglobin
Ahmed, E. M., & Mohamed, A. O. (2014)
Biomarcadores relevantes para diagnóstico precoce e prevenção de doenças cardiovasculares.
Queiroz, J. C. S. (2014)
SIGNIFICANCE OF DETERMINING LEVELS OF APOLIPOPROTEINS A-I AND B IN THE DIAGNOSTICS AND ASSESSMENT OF LIPID-RELATED ATHEROGENIC RISK IN HYPERALPHA-LIPOPROTEINEMIA, HYPOCHOLESTEROLEMIA AND HYPO-HDL-CHOLESTEROLEMIA ZNA^AJ ODRE\IVANJA NIVOA APOLIPOPROTEINA A-I I B U DIJAGNOSTICI I PROCENI ATEROGENOG RIZIKA LIPIDSKOG POREKLA U HIPERALFA-LIPOPROTEINEMIJI, HIPOHOLESTEROLEMIJI I HIPO-HDL-HOLESTEROLEMIJI
Vu, L. (2007)
Análise da relação de qualidade da dieta com nível de atividade física e destes com perfil lipídico e estado inflamatório em indivíduos de risco cardiometabólico
Pública, F. D. S. (2011)

Authors: Chan, D. C.
Affiliations: The University of Western Australia (AU)
Corresponding author: Chan, D.C.
ORCID: Chan, D.C.
Venue: QJM
Publisher: Oxford University Press (OUP)
Published: 2006-02-27
Volume: 99
Issue: 5
Pages: 277-287
ISSN: 0033-5622 (ISSN-L)
1460-2725
1460-2393
DOI: 10.1093/qjmed/hcl027
OpenAlex: W2161147110
Cited by: 117
References: 55
Citations by year: 2026: 1 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 6 · 2021: 2 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 2 · 2014: 9 · 2013: 3 · 2012: 4
FWCI: 1.57
Type: journal article
Language: en
Open access: closed
Locations: QJM (publishedVersion)
PubMed (publishedVersion)
UWA Profiles and Research Repository (UWA) (submittedVersion)
Funders: National Heart Foundation of Australia
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: apolipoprotein B-100, apolipoprotein A-I, coronary artery disease, coronary risk assessment, LDL cholesterol, non-HDL cholesterol, dyslipidemia, triglyceride elevation, lipid profile, atherogenic lipoproteins
MeSH terms: Anticholesteremic Agents, Apolipoproteins, Apolipoproteins B, Cholesterol, Coronary Artery Disease, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Biomarkers, Apolipoprotein A-I, Risk Assessment, Apolipoprotein B-100

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Apolipoproteins as markers and managers of coronary risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks